Literature DB >> 20498076

Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance.

Olga B Garbuzenko1, Maha Saad, Vitaly P Pozharov, Kenneth R Reuhl, Gediminas Mainelis, Tamara Minko.   

Abstract

Development of cancer cell resistance, low accumulation of therapeutic drug in the lungs, and severe adverse treatment side effects represent main obstacles to efficient chemotherapy of lung cancer. To overcome these difficulties, we propose inhalation local delivery of anticancer drugs in combination with suppressors of pump and nonpump cellular resistance. To test this approach, nanoscale-based delivery systems containing doxorubicin as a cell death inducer, antisense oligonucleotides targeted to MRP1 mRNA as a suppressor of pump resistance and to BCL2 mRNA as a suppressor of nonpump resistance, were developed and examined on an orthotopic murine model of human lung carcinoma. The experimental results show high antitumor activity and low adverse side effects of proposed complex inhalatory treatment that cannot be achieved by individual components applied separately. The present work potentially contributes to the treatment of lung cancer by describing a unique combinatorial local inhalation delivery of drugs and suppressors of pump and nonpump cellular resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498076      PMCID: PMC2890783          DOI: 10.1073/pnas.1004604107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model.

Authors:  Moritz Beck-Broichsitter; Julia Gauss; Claudia B Packhaeuser; Kerstin Lahnstein; Thomas Schmehl; Werner Seeger; Thomas Kissel; Tobias Gessler
Journal:  Int J Pharm       Date:  2008-09-19       Impact factor: 5.875

2.  Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.

Authors:  Olga B Garbuzenko; Maha Saad; Seema Betigeri; Min Zhang; Alexandre A Vetcher; Viatcheslav A Soldatenkov; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

Review 3.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

4.  Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery.

Authors:  María José de Jesús Valle; Nora Salamanca Uranga; Francisco Gónzalez López; Alfonso Domínguez-Gil Hurlé; Amparo Sánchez Navarro
Journal:  J Antimicrob Chemother       Date:  2007-09-06       Impact factor: 5.790

Review 5.  The International Epidemiology of Lung Cancer: geographical distribution and secular trends.

Authors:  Danny R Youlden; Susanna M Cramb; Peter D Baade
Journal:  J Thorac Oncol       Date:  2008-08       Impact factor: 15.609

Review 6.  Inhalatory therapy training: a priority challenge for the physician.

Authors:  Andrea S Melani
Journal:  Acta Biomed       Date:  2007-12

7.  Epidemiology of lung cancer prognosis: quantity and quality of life.

Authors:  Ping Yang
Journal:  Methods Mol Biol       Date:  2009

8.  Targeted proapoptotic anticancer drug delivery system.

Authors:  Pooja Chandna; Maha Saad; Yang Wang; Elizabeth Ber; Jayant Khandare; Alexandre A Vetcher; Viatcheslav A Soldatenkov; Tamara Minko
Journal:  Mol Pharm       Date:  2007-08-09       Impact factor: 4.939

9.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

Authors:  Maha Saad; Olga B Garbuzenko; Tamara Minko
Journal:  Nanomedicine (Lond)       Date:  2008-12       Impact factor: 5.307

10.  Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy.

Authors:  Juliane Nguyen; Terry W J Steele; Olivia Merkel; Regina Reul; Thomas Kissel
Journal:  J Control Release       Date:  2008-06-19       Impact factor: 9.776

View more
  51 in total

Review 1.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

2.  Delivery of siRNA to the mouse lung via a functionalized lipopolyamine.

Authors:  Kevin J Polach; Majed Matar; Jennifer Rice; Gregory Slobodkin; Jeff Sparks; Richard Congo; Angela Rea-Ramsey; Diane McClure; Elaine Brunhoeber; Monika Krampert; Andrea Schuster; Kerstin Jahn-Hofmann; Matthias John; Hans-Peter Vornlocher; Jason G Fewell; Khursheed Anwer; Anke Geick
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

Review 3.  siRNA delivery to the lung: what's new?

Authors:  Olivia M Merkel; Israel Rubinstein; Thomas Kissel
Journal:  Adv Drug Deliv Rev       Date:  2014-06-05       Impact factor: 15.470

4.  Liposomally encapsulated CDC20 siRNA inhibits both solid melanoma tumor growth and spontaneous growth of intravenously injected melanoma cells on mouse lung.

Authors:  Anubhab Mukherjee; Jayanta Bhattacharyya; Madamsetty Vijay Sagar; Arabinda Chaudhuri
Journal:  Drug Deliv Transl Res       Date:  2013-06       Impact factor: 4.617

5.  Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells.

Authors:  Chih-Kuang Chen; Wing-Cheung Law; Ravikumar Aalinkeel; Yun Yu; Bindukumar Nair; Jincheng Wu; Supriya Mahajan; Jessica L Reynolds; Yukun Li; Cheng Kee Lai; Emmanuel S Tzanakakis; Stanley A Schwartz; Paras N Prasad; Chong Cheng
Journal:  Nanoscale       Date:  2014       Impact factor: 7.790

6.  Nanoparticle diffusion in respiratory mucus from humans without lung disease.

Authors:  Benjamin S Schuster; Jung Soo Suk; Graeme F Woodworth; Justin Hanes
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

7.  In vitro evaluation of the inhalable quercetin loaded nanoemulsion for pulmonary delivery.

Authors:  Noor Hafizah Arbain; Norazlinaliza Salim; Hamid Reza Fard Masoumi; Tin Wui Wong; Mahiran Basri; Mohd Basyaruddin Abdul Rahman
Journal:  Drug Deliv Transl Res       Date:  2019-04       Impact factor: 4.617

8.  Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Authors:  Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Eur J Pharm Biopharm       Date:  2012-12-08       Impact factor: 5.571

9.  Using Dual Fluorescence Reporting Genes to Establish an In Vivo Imaging Model of Orthotopic Lung Adenocarcinoma in Mice.

Authors:  Cheng-Wei Lai; Hsiao-Ling Chen; Chih-Ching Yen; Jiun-Long Wang; Shang-Hsun Yang; Chuan-Mu Chen
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

10.  Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.

Authors:  G Mainelis; S Seshadri; O B Garbuzenko; T Han; Z Wang; T Minko
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-03-26       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.